Delivery Order SPE2DB20D1100-SPE2DB25FE2Y8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $1,957.32. This competitive, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under a larger contract vehicle, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $3,759.96. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a small-value transaction typical of the company's regular medical supply deliveries...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,633.25 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract utilizes a firm fixed price arrangement with an ultimate completion date of August 8, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $42,114.61. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of August 4, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $8,146.58 and an ultimate completion date of September 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply services under the Defense Logistics Agency's Medical Supply Chain...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,010.26. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $4,552.06. This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a competitively awarded, non-set-aside contract. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $49,655.94. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical supply chains, with performance to take place at the company's...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE2Y8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $1,636.87. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical supply support to federal medical systems through the company's existing contract relationships with the DLA. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, regularly fulfills federal procurement requirements for an extensive portfolio of medications, medical supplies, and specialty pharmaceuticals across multiple therapeutic domains. The award demonstrates the company's continued capability to meet federal medical supply needs through open competition without set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/26/25 |